Skip to content
Screener

Eikon Therapeutics, Inc. EIKN Debt-to-equity

Debt-to-equity at other companies

Gilead Sciences logo
Gilead SciencesGILD
2.2×+1.0×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
0×0.0×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
13.4×+13.3×
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
0×0.0×
Immunome logo
ImmunomeIMNM
0×0.0×
Erasca, Inc. logo
Erasca, Inc.ERAS
0.1×0.0×

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$498.62M-36.3%
Enterprise value$592.29M—

Returns & leverage

See full
Current ratio11.8×—